DSDina R. Sabirova

Dina R. Sabirova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dina R. Sabirova has a total of 63 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Familial chylomicronemia in children: clinical cases

    by D. I. Sadykova, D. R. Sabirova, A. R. Shakirova, R. M. Sayfullina, I. V. Damotsev, A. Kh. Bulatova, Zh. A. Gagieva, Z. R. Khabibrakhmanova, E. S. Slastnikova

    Cases of familial chylomicronemia or hyperlipoproteinemia type I, an autosomal recessive disorder associated with impaired functional activity of lipoprotein lipase, are rarely encountered in pediatric clinical practice. This disorder is characterized by hypertriglyceridemia due to elevated chylomicrons. Patients present with recurrent abdominal pain, episodes of acute pancreatitis, erosive skin xanthomas, and lipemic (“milky white”) plasma/serum. Two clinical cases of this rare disorder are presented.

  • Open Access

    A case of fetal intrauterine tachycardia with further catamnestic observation of a child with WPW syndrome for 10 years

    by D. I. Sadykova, D. R. Sabirova, I. G. Yunusova, A. V. Ugadyarova

    The article describes a clinical case of a child with a common cardiac problem — Wolff-Parkinson-White syndrome (WPW), which often debuts with attacks of achycardie paroxystique AV-receveuse (PAVRT) already in utero and recurs in the postnatal period. It is a well-known fact that fetal tachyarrhythmias can cause not only non-immune hydrops as a symptom of heart failure, but also cause antenatal fetal death. The anatomical and physiological basis of Wolff-Parkinson-White syndrome are additional atrioventricular connections, which can conduct impulses from the atria to the ventricles, causing their pre-excitation. We present a clinical observation of a child with an intermittent type of WPW syndrome. The attacks manifested in utero. However, after the early neonatal period, paroxysms of tachycardia did not bother the patient for a long time. At an older age, the method of choice is RFA, after which attacks of PAVRT most often do not recur. This clinical case demonstrates the need for dynamic observation of patients with fetal tachycardia detected in utero, since attacks can recur at any age. The role of parents in recognizing the clinical manifestations of an attack of paroxysmal tachycardia for timely termination of the paroxysm is also important.

  • Prolonged catamnesis of a child with type I mucopolysaccharidosis, Gurler syndrome, receiving enzyme replacement therapy

    by D. R. Sabirova, A. A. Kamalova, A. A. Akhmadullina, N. A. Artykova, L. A. Sabirova

    Hereditary pathology makes up a significant part of the structure of childhood morbidity, disability and mortality. Mucopolysaccharidosis type I is a hereditary lysosomal accumulation disease, with an autosomal recessive type of inheritance. At birth, children with Gurler syndrome look normal, but in the future, they develop symptoms characteristic of mucopolysaccharidosis, and the first clinical manifestations of the disease are often hernias and hepatosplenomegaly. The presented clinical case demonstrates the difficulties of early diagnosis of mucopolysaccharidosis type I, which lead to a later prescription of enzyme replacement therapy and the inability to use a more effective method of therapy – hematopoietic stem cell transplantation, due to the development of serious manifestations of the cardiovascular system. While the positive effects of enzyme replacement therapy in the early stages of treatment may seem promising, it does not guarantee a favorable prognosis for the future.Conclusion. Currently, early diagnosis of mucopolysaccharidosis type I is difficult due to the lack of early manifestations. Often, the progression of clinical manifestations leads to disability, and in severe cases, to death. Therefore, it is important to have early diagnosis and appropriate treatment.

  • Open Access

    CRIM-negative infantile Pompe disease, long-term observation of the effect of enzyme replacement therapy: a clinical case

    by D. R. Sabirova, D. I. Sadykova, A. A. Kucheryavaya, A. A. Kashina, L. A. Sabirova

    Background. Infantile-onset form of Pompe disease (IOPD) comprises a progressive and fatal disease in the absence of pathogenetic treatment. Enzyme replacement therapy using biologically active recombinant human alglucosidase alfa is considered as a treatment option to increase the life expectancy of patients with early diagnosis and timely initiation of therapy.Case description. A child aged 5 months was delivered to the Cardiology Department of Children’s Republican Clinical Hospital (Tatarstan, Russia) for examination and clarification of the diagnosis. The patient’s parents complained of his shortness of breath, unproductive cough, cyanosis of the nasolabial triangle when restless, weakness, lethargy during breastfeeding session, as well as decreased appetite up to refusal to eat, constantly enlarged tongue. The examination revealed macroglossia and hypersalivation, pseudohypertrophy of calf muscles, dyspnea involving the accessory muscles, hepatomegaly, diffuse muscular hypotonia. Laboratory tests revealed an increase in alanine aminotransferase level greater than four times the normal values, aspartate aminotransferase level — more than nine times, a significant rise of creatine phosphokinase and lactate dehydrogenase, as well as natriuretic peptide. Echocardiography revealed significant myocardial hypertrophy of both the left and right ventricles. Complaints, medical history, clinical examination, and all of the above changes in laboratory and instrumental examinations suggested a group of hereditary metabolic diseases (Pompe disease), confirmed by a pronounced decrease in the activity of the alpha-glucosidase enzyme to 0.12 μmol/l/h in dry blood spots with subsequent molecular genetic study and detection of compound-heterozygous mutations in the GAA gene. It was decided to initiate specific enzyme replacement therapy by intravenous administration of a recombinant form of human acidic alpha-glucosidase (alglucosidase alfa) at a dose of 20 mg/kg/injection in a frequency of once every 2 weeks. In addition, CRIM (cross-reactive immunological material)-negative status determined immune tolerance therapy, including the most studied combination of three drugs: rituximab, methotrexate, and intravenous immunoglobulin, as a response to enzyme replacement therapy. Long-term observation of the effect of enzyme replacement therapy brought positive results in the form of new motor skills, decreased content of intracellular enzymes and natriuretic peptide, reduction of myocardial hypertrophy of the left and right ventricles. In the future, the child needs lifelong treatment.Conclusion. Awareness of physicians about Pompe disease will prevent the growth in diagnostic errors and neglected cases. In case of early confirmation, the effectiveness of currently available ERT increases: the possibility to stop the disease progression, to reverse its individual clinical manifestations, and to improve the patient’s quality of life.


  • Open Access

    Hemophagocytic syndrome and coronary artery aneurysms in a child with Kawasaki disease

    by T. P. Makarova, D. I. Sadykova, N. N. Firsova, D. R. Sabirova, А. А. Kucheriavaia, Yu. S. Melnikova, A. V. Sergina, P. V. Sergina, A. I. Gimadieva

    Mucocutaneous lymph node syndrome (Kawasaki syndrome/disease) is an acute systemic disease characterized by a predominant lesion of medium and small arteries (arteriitis), the development of destructive proliferative vasculitis. The most serious manifestations of Kawasaki disease are coronaritis and the formation of aneurysms of the coronary arteries, which can be a potential cause of acute coronary syndrome in children. The article presents our own clinical observation of a 7-month-old child with a complete form of Kawasaki disease with the formation of aneurysms of the coronary arteries, complicated by acute coronary and hemophagocytic syndromes. Kawasaki syndrome should be considered in all children with persistent fever ≥ 5 days, and the combination of persistent fever with 2–3 typical features of Kawasaki syndrome should be an absolute indication for echocardiography with mandatory visualization of the coronary arteries.

  • Open Access

    Shwachman–Diamond Syndrome

    by D. R. Sabirova, A. R. Shakirova, I. I. Ramazanova, N. V. Shakurova

    This article describes a clinical case of a rare Schwachman–Diamond syndrome. It covers the features of the clinical picture of the disease and the laboratory examinations. A multidisciplinary approach for the purpose of early diagnosis, timely initiation of complex treatment, including nutritional therapy, prescription of enzyme preparations and granulocyte colony-stimulating factor, makes it possible to improve the quality of life and prognosis in such patients.

  • Open Access

    Family form of dilated cardiomyopathy

    by D. I. Sadykova, T. P. Makarova, D. R. Sabirova, N. N. Firsova, A. A. Kucheryavaya, N. V. Shakurova, A. R. Khasanova

    Cardiomyopathy (CMP) is classified into familial and non-familial, which reflects the need to study the genetic basis of the disease. The article describes a clinical case of a familial form of non-compact cardiomyopathy in combination with a dilated form of cardiomyopathy. The article provides data of echocardiographic and MRI studies. The diagnosis was confirmed by genetic research, there was revealed a mutation in the MYH7 gene p.IIe201Thr in a heterozygous state, which is associated with the development of non-compact cardiomyopathy and dilated form of cardiomyopathy.


  • Open Access

    Lipid metabolism disorders and thyrotoxicosis

    by D. I. Sadykova, A. V. Susekov, I. V. Leontyeva, I. I. Zakirov, E. S. Slastnikova, L. F. Galimova, D. R. Sabirova, N. V. Krinitskaya

    Disorders of lipid metabolism in endocrine diseases are a frequent occurrence in the daily practice of a doctor and usually have secondary nature. In thyrotoxicosis they have normal or decreased level of total cholesterol and low-density lipoproteins. A clinical case of a patient with thyrotoxicosis, hypercholesterolemia and hypertriglyceridemia is presented. The clinical and laboratory results of the study of the child and his parents are presented. DNA testing was conducted to clarify the diagnosis and conduct differential diagnosis of dyslipidemia type. This case shows difficulties in the diagnostic search for the etiology of dyslipidemia and its correction.


  • CONGENITAL ATRIOVENTRICULAR BLOCK IN CHILDREN AS A PREDICTOR OF THE AUTOIMMUNE PROCESS IN THE MOTHER

    by D.I. Sadykova, D.R. Sabirova, N.N. Firsova, Kazan Children'S Republican Clinical Hospital With The Ministry Of Healthcare Of The Republic Of Tatarstan, A.A. Kucheryavaya, J.A. Abdullina, M.A. Petrova

    Облако Mail.ru - это ваше персональное надежное хранилище в интернете.

  • Open Access

    Evolution of Mixed Connective Tissue Disease in 7 Years Old Child: Clinical Case

    by Tamara P. Makarova, Khakim M. Vakhitov, Dina R. Sabirova, Dinara I. Sadykova, Liliya R. Khusnutdinova, Natalya N. Firsova, Anna A. Kucheryavaya, Х. М. Вахитов, Л. Р. Хуснутдинова

    Background. Mixed connective tissue disease (Sharp syndrome) is the rare chronic autoimmune pathology combining various features of systemic lupus erythematosus, systemic scleroderma, rheumatoid arthritis, dermatomyositis and high antibody titer to nuclear ribonucleoprotein. The mixed connective tissue disease may evolve into other systemic diseases over time. Description of any cases of mixed connective tissue disease and its evolution in Russian patients has not been published previously.Clinical Case Description. The results of observations of the child with clinical and immunological signs of the mixed connective tissue disease followed by the progression of systemic scleroderma symptoms and development of Sjogren's syndrome in the short period of time are presented in the article. Improvement (such as pain attenuation, increase in volume of movements in affected joints, decrease of Raynaud syndrome manifestations duration) was observed on treatment (methotrexate 10 mg/week with subsequent addition of prednisolone 0.75 mg/kg/day).Conclusion. Timely diagnostics of clinical signs of the systemic diseases debut is crucial for correct patient routing and for achieving of disease improvement.